John Hopkin’s University Publishes Efficacy of QuadraMune™ Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory Studies
Commercially Available Nutraceutical Developed by Phase III Stem Cell Biotechnology Company Continues to Receive Independent Validation of Potential Benefit in SARS-CoV-2 Strains
Data generated by the researchers independent of
In the publication abstract, the researchers concluded, “Our results suggest that sulforaphane should be explored as a potential agent for the prevention or treatment of coronavirus infections.”
“As a physician who is currently leading an FDA-cleared Phase III clinical trial for advanced COVID-19 patients, I am extremely excited to see that our nutraceutical program is receiving independent validation based on research published from world-class institutions,” said Dr.
The Company possesses two issued United States Patents for use of QuadraMune™ in the area of Immune Modulation (#11,229,674) and treatment of Coronavirus (#11,266,707). After the Company filed its first patent on QuadraMune on
“Our successes are based on the fact that we at
QuadraMune™ is available commercially from Amazon and Walmart.
About
1 Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice | Communications Biology (nature.com)
2 Therapeutic Solutions International Discusses Claims of Possible COVID-19 Suppressive Activity of QuadraMune™ Ingredients by Independent Universities Made After Patent Filing (yahoo.com)
View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005213/en/
ir@tsoimail.com
Source: